Diagnostic and therapeutic pathways for the malignant left atrial appendage: EHRA physician survey.

Ante Anić Darija Bakovic Zrinka Jurisic Michal Miroslaw Farkowski Lucija Lisica Kordić Toni Brešković Jens Erik Nielsen Kudsk Laura Perrotta Carlos De Asmundis Serge Boveda Kyoung-Ryul Julian Chun

Published in: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2023)

This EHRA survey provides snapshot of the contemporary management of patients diagnosed with malignant LAA. Currently, the majority of patients are treated on an outpatient basis with either shifting VKA to DOAC or from one DOAC to another. LAAC in this population seems to be reserved for patients with higher bleeding risk or complications of malignant LAA such as stroke.

Keyphrases

atrial fibrillation
left atrial appendage
direct oral anticoagulants
newly diagnosed
end stage renal disease
ejection fraction
cross sectional
primary care
prognostic factors
catheter ablation
patient reported
blood brain barrier